Bellerophon Therapeutics, which is developing drug-device combination therapies for pulmonary and cardiac diseases, announced terms for its IPO on Tuesday. The Hampton, NJ-based company plans to raise $60 million by offering 4.0 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Bellerophon would command a fully diluted market value of $184 million.
Bellerophon Therapeutics, which was founded in 2013, plans to list on the NASDAQ under the symbol BLPH. Leerink Partners and Cowen & Company are the joint bookrunners on the deal. It is expected to price during the week of February 9, 2015.
